File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib

TitleThe significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib
Authors
KeywordsAlpha-fetoprotein
Hepatocellular carcinoma
Sorafenib
Surrogate
Issue Date2011
PublisherAlphaMed Press, Inc. The Journal's web site is located at http://www.theoncologist.org/
Citation
Oncologist, 2011, v. 16 n. 9, p. 1270-1279 How to Cite?
AbstractBackground. The role of serum alpha-fetoprotein (AFP) changes in predicting the treatment outcomes of advanced hepatocellular carcinoma (HCC) patients to sorafenib remains unknown. Methods. Serum AFP was collected prospectively at baseline and subsequent follow-up visits in parallel with clinical and survival outcomes. AFP response was defined as a relative drop of AFP >20% of the baseline level after 6 weeks of sorafenib. The relationship between AFP response and the treatment outcomes was first explored in patients who received sorafenib in a phase II study. Subsequently, an independent validation set of patients were obtained to validate the association of AFP response to clinical outcomes. Results. Included in the exploration and validation sets for analysis were 41 and 53 patients, respectively, with baseline AFP level >20 μg/L. In the exploration cohort, AFP response was significantly associated with clinical benefit (CB) rate (relative chance 3.4, 95% confidence interval [CI], 1.1-11.1), and multi-variate analysis indicated that AFP response was associated with significantly better progression-free survival (PFS) (hazard ratio [HR], 0.31; 95% CI, 0.13- 0.76) and marginally better overall survival (OS) (HR, 0.30; 95% CI, 0.09-1.02). When applying AFP changes in the validation set, significant associations were again found between AFP response with CB rate (relative chance, 5.5; 95% CI, 2.3-13.6) and PFS (HR, 0.12; 95% CI, 0.04-0.30) but not OS (HR, 0.61; 95% CI, 0.27-1.26). Conclusion. Drop in AFP level at 6 weeks is an exploratory early surrogate for both CB and PFS in advanced HCC patients receiving sorafenib. © AlphaMed Press.
Persistent Identifierhttp://hdl.handle.net/10722/142544
ISSN
2015 Impact Factor: 4.789
2015 SCImago Journal Rankings: 2.391
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYau, Ten_HK
dc.contributor.authorYao, TJen_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorWong, Hen_HK
dc.contributor.authorPang, Ren_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorPoon, RTPen_HK
dc.date.accessioned2011-10-28T02:50:56Z-
dc.date.available2011-10-28T02:50:56Z-
dc.date.issued2011en_HK
dc.identifier.citationOncologist, 2011, v. 16 n. 9, p. 1270-1279en_HK
dc.identifier.issn1083-7159en_HK
dc.identifier.urihttp://hdl.handle.net/10722/142544-
dc.description.abstractBackground. The role of serum alpha-fetoprotein (AFP) changes in predicting the treatment outcomes of advanced hepatocellular carcinoma (HCC) patients to sorafenib remains unknown. Methods. Serum AFP was collected prospectively at baseline and subsequent follow-up visits in parallel with clinical and survival outcomes. AFP response was defined as a relative drop of AFP >20% of the baseline level after 6 weeks of sorafenib. The relationship between AFP response and the treatment outcomes was first explored in patients who received sorafenib in a phase II study. Subsequently, an independent validation set of patients were obtained to validate the association of AFP response to clinical outcomes. Results. Included in the exploration and validation sets for analysis were 41 and 53 patients, respectively, with baseline AFP level >20 μg/L. In the exploration cohort, AFP response was significantly associated with clinical benefit (CB) rate (relative chance 3.4, 95% confidence interval [CI], 1.1-11.1), and multi-variate analysis indicated that AFP response was associated with significantly better progression-free survival (PFS) (hazard ratio [HR], 0.31; 95% CI, 0.13- 0.76) and marginally better overall survival (OS) (HR, 0.30; 95% CI, 0.09-1.02). When applying AFP changes in the validation set, significant associations were again found between AFP response with CB rate (relative chance, 5.5; 95% CI, 2.3-13.6) and PFS (HR, 0.12; 95% CI, 0.04-0.30) but not OS (HR, 0.61; 95% CI, 0.27-1.26). Conclusion. Drop in AFP level at 6 weeks is an exploratory early surrogate for both CB and PFS in advanced HCC patients receiving sorafenib. © AlphaMed Press.en_HK
dc.languageengen_US
dc.publisherAlphaMed Press, Inc. The Journal's web site is located at http://www.theoncologist.org/en_HK
dc.relation.ispartofOncologisten_HK
dc.subjectAlpha-fetoproteinen_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectSorafeniben_HK
dc.subjectSurrogateen_HK
dc.titleThe significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafeniben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1083-7159&volume=16&issue=9&spage=1270&epage=1279&date=2011&atitle=The+significance+of+early+alpha-fetoprotein+level+changes+in+predicting+clinical+and+survival+benefits+in+advanced+hepatocellular+carcinoma+patients+receiving+sorafeniben_US
dc.identifier.emailYau, T: tyaucc@hku.hken_HK
dc.identifier.emailYao, TJ: tjyao@hkucc.hku.hken_HK
dc.identifier.emailPang, R: robertap@hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailPoon, RTP: poontp@hku.hken_HK
dc.identifier.authorityYau, T=rp01466en_HK
dc.identifier.authorityYao, TJ=rp00284en_HK
dc.identifier.authorityPang, R=rp00274en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1634/theoncologist.2011-0105en_HK
dc.identifier.pmid21885876-
dc.identifier.pmcidPMC3228178-
dc.identifier.scopuseid_2-s2.0-80053212846en_HK
dc.identifier.hkuros196689en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80053212846&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume16en_HK
dc.identifier.issue9en_HK
dc.identifier.spage1270en_HK
dc.identifier.epage1279en_HK
dc.identifier.eissn1549-490X-
dc.identifier.isiWOS:000295254100008-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYau, T=23391533100en_HK
dc.identifier.scopusauthoridYao, TJ=7401886444en_HK
dc.identifier.scopusauthoridChan, P=7403497715en_HK
dc.identifier.scopusauthoridWong, H=23089414000en_HK
dc.identifier.scopusauthoridPang, R=7004376659en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats